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Abstract
Introduction: Medullary thyroid cancer (MTC) is a malignancy of the thyroid gland, which derives from parafollicular C cells. Periodic measure-
ment of biochemical markers of MTC remains a crucial part of patient follow-up and disease monitoring. The aim of the study was to compare 
the diagnostic value of four selected markers — calcitonin (Ct), procalcitonin (PCT), chromogranin A (CgA), and carcinoembryonic antigen (CEA).
Material and methods: Patients with histopathologically confirmed MTC hospitalised in a single department between January 2015 and 
December 2015 were included in the study. Patients were subdivided into two groups: a remission group and an active disease group, 
based upon serum markers of MTC and imaging. Levels of Ct, PCT, CgA, and CEA were compared between the groups.
Results: Forty-four patients were included; 20 patients presented active disease and 24 were in remission. All patients with active disease 
had Ct exceeding the upper limit of normal range (10 pg/mL) — for that threshold the sensitivity was 100.0% and the specificity was 73.9%; 
for the best-fit threshold of 121.0 pg/mL the specificity was 95.8% with sensitivity 100.0%. There was significant correlation between Ct 
and PCT — p < 0.000001, r = 0.93. All patients with active disease exceeded the upper limit of the normal range (0.5 ng/mL) — for that 
threshold the sensitivity was 100.0% and the specificity was 83.3%; for the best-fit threshold of 0.95 ng/mL the specificity was 95.8% with 
sensitivity 100.0%. In case of CEA for the best-fit threshold of 12.66 ng/mL the specificity was 100.0% with sensitivity 57.9%; for CgA the 
best-fit threshold was 75.66 ng/mL with specificity 83.3% and sensitivity 75.0%.
Conclusions: Our study confirms that PCT can be considered as an equivalent alternative for measurement of calcitonin. On the other 
hand, it is also worth noting that MTC can be a rare cause of very high levels of PTC not resulting from infectious diseases. The diagnostic 
value of CEA and chromogranin A is much lower and can be within the normal range even in patients with advanced, metastatic MTC. 
They should be used only as accessory markers.  (Endokrynol Pol 2017; 68 (4): 434–437)
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Streszczenie
Wstęp: Rak rdzeniasty tarczycy (RRT) to nowotwór złośliwy tarczycy wywodzący się z przypęcherzykowych komórek C. Okresowa kon-
trola markerów biochemicznych RRT stanowi kluczowy element prowadzenia pacjenta i monitorowania choroby. Celem obecnej pracy 
było porównanie wartości diagnostycznej czterech wybranych markerów — kalcytoniny (Ct), prokalcytoniny (PCT), chromograniny A 
(CgA) i antygenu karcynoembrionalnego (CEA). 
Metody: Do badania włączono pacjentów z histopatologicznie potwierdzonym RRT hospitalizowanych w jednym oddziale szpitalnym 
w 2015 roku. Pacjentów podzielono na dwie podgrupy — grupę pacjentów w remisji oraz z aktywną chorobą zależnie od wartości mar-
kerów osoczowych oraz wykonanej diagnostyki obrazowej. 
Wyniki: Włączono czterdziestu czterech pacjentów; 20 pacjentów prezentowało cechy aktywnej choroby, 24 było w remisji. Wszy-
scy pacjenci z aktywną chorobą wykazywali stężenia Ct przekraczające górną granicę normy (10 pg/ml); dla optymalnego punktu 
odcięcia 121,0 pg/ml swoistość wyniosła 95,8% przy czułości 100,0%. Wykazano istotną korelację pomiędzy Ct i PCT- p < 0.000001, 
r = 0.93. Dla optymalnego punktu odcięcia wynoszącego 0.95 ng/ml swoistość wyniosła 95.8% przy czułości 100.0%. W przypadku 
CEA dla najlepiej dopasowanego progu 12,66 ng/ml swoistość wyniosła 100,0% przy czułości 57,9%; dla CgA optymalny punkt odcięcia 
wyniósł 75,66 ng/ml przy swoistości 83,3% i czułości 75,0%. 
Wnioski: Nasze badanie potwierdza, że PCT może być uważana za równoważną alternatywę dla oznaczenia kalcytoniny. Wartość 
diagnostyczna CEA i chromograniny A jest znacznie mniejsza i parametry te mogą pozostawać w granicach normy nawet u pacjentów 
z zaawansowanym RRT z przerzutami odległymi. Powinny być one traktowane jedynie jako pomocnicze markery. 
(Endokrynol Pol 2017; 68 (4): 434–437)
Słowa kluczowe: prokalcytonina; kalcytonina; rak rdzeniasty tarczycy; chromogranina A; antigen karcynoembrionalny
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Introduction
Medullary thyroid cancer (MTC) is a malignancy of the 
thyroid gland, which derives from parafollicular C cells 
[1, 2]. According to numerous studies it accounts for 
about 1–5% of all thyroid cancer (TC) and over 10% of 
mortalities associated with thyroid malignancies [1–4]. 
Several aspects of management of MTC remain 
a challenge. Initial diagnosis may often be delayed 
because MTCs frequently present as relatively benign 
lesions on sonographic examination and confounding 
results of fine-needle aspiration biopsy (FNAB) [5, 6]. 
Follow-up and detection of recurrence can be chal-
lenging, due to common difficulties in localisation of 
neoplastic masses and discrepancies between results 
of commonly used biochemical markers [7].
Early detection of MTC recurrence is essential be-
cause surgery remains the only effective form of treat-
ment [1, 8, 9]. Periodic measurement of biochemical 
markers of MTC remains — besides neck ultrasonog-
raphy — the most important part of the follow-up 
[1, 2, 10]. The aim of the current study was to compare 
the diagnostic value of four selected markers — calci-
tonin (Ct), procalcitonin (PCT), chromogranin A (CgA), 
and carcinoembryonic antigen (CEA). 
Material and methods
Patients
Patients included in the study with histopathologi-
cally confirmed MTC were hospitalised in a single 
department from January 2015 to December 2015. All 
patients underwent thyroidectomy and were admitted 
for biochemical and radiological control examinations. 
Patients were divided into two groups: a remission 
group and an active disease group based upon several 
criteria. The criteria used to divide the patients into 
the groups included MTC serum markers, neck ultra-
sound examination, chest X-ray, and CT examinations 
including the neck, chest, and abdomen in the case of 
abnormal initial examination. The study was approved 
by the Poznan University of Medical Sciences Ethical 
Committee. Written informed consent was given by 
all participants.
Laboratory methods
Ct and CgA were measured using radioimmunological 
method. CEA and PCT were measured using chemi/
electroluminescent method.
Statistical analysis
All calculations were performed using Statistica v.12 
from Statsoft. A p-value under 0.05 was considered 
statistically significant. Correlations were calculated 
using Spearman’s rank correlation coefficient due to 
lack of normal distribution of Ct.
Results
Forty-four patients were included; there were 27 fe-
males and 17 males. Mean age was 55.6 ± 14.6 years. 
Twenty patients presented active disease and 24 were 
in remission. 
Calcitonin
Patients with active malignancy had calcitonin levels 
121.1 up to 65826.0, median 2548.0 pg/ml, and in patients 
in remission, 0.5–233.3, median 3.16 pg/mL. All patients 
with active disease exceeded the upper limit of normal 
range (10 pg/mL) — for that threshold the sensitivity 
was 100.0%, specificity 73.9%; for the best-fit threshold 
of 121.0 pg/mL the specificity was 95.8% with sensitivity 
100.0% (Fig. 1). 
Procalcitonin 
There was significant correlation between Ct and PCT, 
p < 0.000001, r = 0.93. Patients with active disease had 
procalcitonin levels ranging from 0.96 to 400.0, median 
23.45 ng/mL. Patients in remission had levels from 
0.02 to 1.0, median 0.04 ng/dL. All patients with active 
disease exceeded the upper limit of the normal range 
(0.5 ng/mL) — for that threshold the sensitivity was 
100.0%, specificity 83.3%; for the best-fit threshold of 
0.95 ng/mL the specificity was 95.8% with sensitivity 
100.0% (Fig. 1).
Carcinoembryonic antigen 
There was a significant correlation between Ct and CEA 
— p < 0.000001, r = 0.75. Patients with active disease 
presented CEA levels from 1.64 to 1000.0, median 21.22 
ng/mL. Patients in remission had levels from 0.52–12.40, 
median 1.45 ng/dL. Among patients with active disease 13 
exceeded the upper limit of normal range (5 ng/mL) — for 
that threshold the sensitivity was 65.0% and the specific-
ity was 79.2%; for the best-fit threshold of 12.66 ng/mL 
the specificity was 100.0% with sensitivity 57.9% (Fig. 1).
Chromogranin A
There was significant correlation between Ct and CgA 
— p = 0.000004, r = 0.63. Patients with active disease 
had CgA levels of 38.0–9127.0, median 125.01 ng/mL. 
Patients in remission had levels from 26.14–387.95, me-
dian 49.1 ng/mL. Among patients with active disease 11 
exceeded the upper limit of normal range (100 ng/mL) 
— for that threshold the sensitivity was 55.0% and the 
specificity was 83.3%; for the best-fit threshold of 75.66 
ng/mL the specificity was 83.3% with sensitivity 75.0% 
(Fig. 1).
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Discussion
Periodic monitoring of serum markers plays a crucial role 
in the management of patients with MTC and enables 
early detection of disease recurrence. Calcitonin — as 
a physiological product of parafollicular C-cells — re-
mains the most sensitive and most commonly used 
marker, characterised by good correlation with the clini-
cal stage of MTC [1, 2, 11, 12]. Procalcitonin is a peptide 
composed of 116 amino-acids, which is subsequently 
processed to mature calcitonin containing 32 amino ac-
ids. Initially PCT was described as a marker of systemic 
inflammation, production of which can be stimulated 
directly by bacterial endotoxins and indirectly by inflam-
matory mediators [13]. However, PCT — as precursor 
of Ct — was also considered as an alternative marker of 
MTC [14, 15]. PCT has numerous advantages in compari-
son to Ct resulting from biological and practical reasons. 
It is a very stable protein with an in vivo half live about 20 
hours [14]. Its measurement is widely available, eliminat-
ing the need for a highly specialised hospital laboratory. 
Moreover, laboratory sets for PCT are also more readily 
standardised, and results from different laboratories 
are easier to compare when contrasted with Ct because 
all available sets use the same antibodies, which lends 
itself to a higher level of performing measurements 
[14, 16]. Finally, the results of PCT measurements are 
more readily available because it is an examination 
usually performed in urgent conditions, whereas the 
waiting period for the results of a Ct measurement is 
Figure 1. Receiver operating characteristic curves for calcitonin (A), procalcitonin (B), carcinoembryonic antigen (C), and chromogranin A (D)
Rycina 1. Krzywa ROC dla kalcytoniny (A), prokalcytoniny (B), antygenu karcynoembrionalnego (C) i chromograniny A (D)
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substantially longer. PCT could be a preliminary analysis 
allowing for assessment if a patient is at high or low risk 
of recurrence, and consequently used to decide if basic 
imaging (thyroid ultrasonography, chest radiography) is 
sufficient or if comprehensive scanning for localisation 
of metastases is needed.
According to our results, the correlation between 
Ct and PCT levels is extremely high with a Spearmans’ 
rank coefficient approaching 1. Association between Ct 
and PCT levels was very high in patients in remission 
as well as in patients with disseminated neoplastic 
disease. Both markers achieved the same sensitivity 
and specificity. 
There were few previously published studies on 
the topic of the application of PCT in the diagnostics 
of recurrence of MTC. Most of them reported high 
very high sensitivity of PCT, ranging from 84.0 [13] to 
100.0% [11, 15, 18, 19] with more differentiated values of 
specificity — from 57 [18] to 100% [20]. The mentioned 
studies adapted different cut-off levels of PCT — from 
0.1 to 0.5 ng/mL. To our knowledge, the current study 
is the first one that not only assesses the diagnostic 
value of PCT but also compares it with other available 
markers of MTC.
As well as calcitonin, there are also some non-specific 
markers of MTC such as CEA or chromogranin A. It is 
recommended to monitor these markers to detect recur-
rence of poorly differentiated MTC with low expression 
of calcitonin; CEA is most commonly recommended as 
such an additional marker [2]. According to our results, 
despite quite strong correlation between CEA and Ct 
levels, the specificity and especially sensitivity of CEA 
is much lower. In more than one-third of patients with 
active MTC CEA was within the normal range, includ-
ing individual with massive recurrence in the thyroid 
bed and metastases to the lymph nodes and lungs with 
a calcitonin level of almost 3000 pg/mL and CEA under 
2 ng/mL. This observation provides evidence that even 
in patients with very advanced MTC CEA can be falsely 
negative.
The sensitivity achieved for chromogranin A was 
slightly better than for CEA with lower specificity. 
However, the threshold for CgA determined with the 
use of ROC (receiver operating characteristic) curve was 
within the normal range for healthy person. Therefore, 
the use of such a threshold can be considered controver-
sial, especially because the CgA level can increase above 
the normal range due to numerous non-neoplastic 
conditions, such as treatment with inhibitors of proton 
pump, liver failure, heart failure, inflammatory bowel 
diseases, stress, intensive physical activity, etc. [21, 22]. 
Only a minority of our patients with MTC had undoubt-
edly increased levels of CgA; less than one third had 
results exceeding twice the upper limit of the normal 
range, and such an elevation of CgA was characteristic 
for patients with very advanced metastatic MTC. 
In conclusion, our study confirms that PCT can be 
considered as an equivalent alternative of calcitonin 
in the case of patients with MTC. On the other hand, 
it is also worth remembering that MTC can be a rare 
cause of very high levels of PCT not resulting from 
infectious diseases. The diagnostic value of CEA and 
chromogranin A is much lower and can be within 
the normal range even in patients with advanced, 
metastatic MTC. They can be used only as accessory 
markers; CEA seems to be more valuable in this role 
due to its higher sensitivity.
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